Lithuanian company VUGENE raises €1M

Lithuanian startup VUGENE announced the closing an investment round of €1M led by Finnish Superhero Capital backed by NGL Ventures, Coinvest Capital and a group of angel investors.

VUGENE, a company founded in Lithuania in 2021 by Juozas Gordevičius, has developed a platform that can integrate complex biological data from different sources, which greatly facilitates biomedical research. The startup's current customers include Corewell Health, Barrow Neurological Institute, Epigenetic Clock Development Foundation, Rush University Medical Center, rAAVen Therapeutics, and Biocrates. The CEO of the company is Gražina Mykolaitytė.

With the investment, VUGENE plans to use the new funds to scale its platform globally, expanding research and development capabilities in a variety of areas including neurodegenerative diseases, cancer, gene therapy and cardiovascular research.

Superhero Capital is a venture capital firm founded in 2015 in Helsinki, Finland. It focuses on investing in early stage software startups, mainly in Finland and the Baltics. In January 2025, Superhero Capital launched its fourth €50M fund, which focuses on investing in early-stage startups in Finland and the Baltics.

NGL Ventures was founded in April 2024 in Lithuania by former LitBAN Managing Director Justinas Pasys and Ieva Dargyte-Pasiene as a family business. There are 92 members in the network. NGL has placed eight advisory board members in four startups.

Coinvest Capital, an early stage venture capital fund established in 2018 by the national development bank ILTE, invests EU and Republic of Lithuania public funds, in promising Lithuanian startups. Since its inception, the fund and its partners have already invested €37.9M in 39 startups. The managing director of Coinvest Capital is Viktorija Trimbel.